Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

Articles

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year overall survival rates.

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Larazotide, a therapy known to treat celiac disease, shows promise as a safe treatment for multisystem inflammatory syndrome in children linked to COVID-19, enhancing recovery and symptom resolution.

Celiac Disease Therapy Provides Benefit for Children With GI Conditions After COVID-19

The Commonwealth Fund’s updated July 2025 brief on maternal mortality highlights how systemic disparities, Medicaid coverage gaps, and behavioral health challenges continue to drive poor maternal and infant outcomes across the United States.

Confronting the Maternal Mortality Crisis in the United States: Insights From the 2025 Commonwealth Fund Brief

Laura is the vice president of content for 

) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.

Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Advancing Diabetes Care: The Future of Continuous Glucose Monitoring in the Management of Diabetes 

Video Series

CGM vs Traditional Monitoring

Video content above is prompted by the following:

What clinical and practical factors guide your decision-making when recommending CGMs versus vs traditional glucose monitoring for patients with type 2 diabetes?

Videos

This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations, addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.

This program was supported through an independent medical education grant from Dexcom Medical Affairs.

A panelist discusses how continuous glucose monitoring (CGM) technology can help overcome therapeutic inertia and key barriers to glycemic control in type 2 diabetes (T2D) patients by providing real-time data that enables earlier interventions, supports treatment optimization, and helps managed care organizations justify broader CGM adoption for newly diagnosed patients.

CGM: Redefining Type 2 Diabetes Management

This program was supported through an independent medical education grant from Dexcom Medical Affairs.

Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with traditional monitoring based on recent clinical trial data, including research on cardiovascular risk reduction in noninsulin-treated T2D.

Key Benefits of CGM Technology

This program was supported through an independent medical education grant from Dexcom Medical Affairs.

Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and supports earlier therapeutic interventions across different patient populations, highlighting measurable improvements in patient outcomes, such as glycemic control, hemoglobin A1c (HbA1c) levels, hypoglycemic events, and quality of life.

CGM's Impact on Clinical Inertia

Experts discuss the clinical and practical factors that guide decision-making when recommending continuous glucose monitoring (CGM) vs traditional glucose monitoring for patients with type 2 diabetes.

Experts discuss the relative value of different continuous glucose monitoring (CGM) metrics (glucose management indicator [GMI], time in range, glucose variability) in assessing glycemic control and how these outcomes vary across different patient populations.

Understanding CGM Metrics

Experts discuss the role of continuous glucose monitoring (CGM)-derived metrics, particularly glucose management indicator (GMI), in the new Healthcare Effectiveness Data and Information Set (HEDIS) diabetes care measures and ACO quality targets, and how CGM-specific metrics are being incorporated into the National Committee for Quality Assurance (NCQA)’s quality measures and the implications for health plans.

Health Care System Integration

Experts discuss how the integration of continuous glucose monitoring (CGM) data into electronic health record (EHR) systems enhances clinical decision-making and care coordination, how primary care providers (PCPs) can leverage CGM data integration to provide more comprehensive diabetes care in the context of a shortage of endocrinologists, and the impact of varying coverage policies for CGM across different payers on patient access and outcomes, particularly for patients on basal insulin.

CGM Coverage and Access

Experts discuss the most significant barriers to continuous glucose monitoring (CGM) implementation encountered in their respective roles and how these barriers vary across different patient populations and care settings.

Implementation Barriers

Experts discuss how current coverage policies and prior authorization requirements affect continuous glucose monitoring (CGM) access and adoption rates, and how coverage barriers impact the ability to provide timely CGM access, particularly for patients who could benefit most.

Overcoming Access Challenges

Experts discuss the disparities observed in continuous glucose monitoring (CGM) access and utilization with Healthcare Effectiveness Data and Information Set (HEDIS) now stratifying 22 measures by race and ethnicity, and how these insights can inform strategies to improve health equity, along with successful strategies implemented to improve CGM access and technology literacy in underserved communities.

Adoption Strategies

Experts discuss how to evaluate and communicate the return on investment for continuous glucose monitoring (CGM) coverage to overcome cost-related barriers, explore strategies other payers could adopt based on the success of Metro Nashville Public Schools' initiative to provide CGM devices without prior authorization, and examine the impact of removing prior authorization requirements on appropriate patient selection and utilization, along with which aspects of this model could be adopted by other employers and the resources needed to implement similar programs.

The Metro Nashville Public Schools Initiative

Experts discuss the impact of continuous glucose monitoring (CGM) implementation on emergency department utilization, hospitalizations, and quality measures including Healthcare Effectiveness Data and Information Set (HEDIS)/Medicare Star ratings, and how CGM adoption has influenced patient encounter patterns, care coordination efficiency, and achievement of quality benchmarks.

Health Care Quality Impact

Experts discuss the metrics used to evaluate continuous glucose monitoring (CGM)'s comprehensive return on investment, including both cost savings and quality measure performance, and identify which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, along with how these groups are prioritized for CGM access.

Population Outcomes and Return on Value With CGMs 

Experts share specific examples of how continuous glucose monitoring (CGM) technology has impacted diabetes-related health care costs and quality performance metrics, and discuss the methods used to measure and track CGM's long-term impact on diabetes complications, associated costs, and quality outcomes.

Long-Term Outcomes Assessment

Experts discuss how to evaluate the cost-effectiveness of continuous glucose monitoring (CGM) compared to traditional monitoring, considering both clinical and quality outcomes, and what combination of economic and quality data would most effectively support broader CGM adoption across health systems and payer organizations.

CGM vs Traditional Monitoring

EP: 1.CGM: Redefining Type 2 Diabetes Management

EP: 2.Key Benefits of CGM Technology

EP: 3.CGM's Impact on Clinical Inertia

EP: 4.CGM vs Traditional Monitoring

EP: 5.Understanding CGM Metrics

EP: 6.Health Care System Integration

EP: 7.CGM Coverage and Access

EP: 8.Implementation Barriers

EP: 9.Overcoming Access Challenges

EP: 10.Adoption Strategies

EP: 11.The Metro Nashville Public Schools Initiative

EP: 12.Health Care Quality Impact

EP: 13.Population Outcomes and Return on Value With CGMs

EP: 14.Long-Term Outcomes Assessment

EP: 15.Closing Perspectives